3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
10
OTHER_GOV
2
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Classical hematology
2
Tumor-Agnostic
1
Conditions
Lymphoproliferative Disorders
2
Anemia, Iron-Deficiency
2
Anemia
2
Interventions
Epoetin Alfa
38
Darbepoetin alfa
30
epoetin beta
10
Rivaroxaban
9
olaparib
5
eltrombopag
5
apixaban
5
Heparin, Low-Molecular-Weight
5
pegylated granulocyte colony-stimulating factor
4
pegfilgrastim
4
emicizumab
4
Gemcitabine
4
Filgrastim
4
Dalteparin
4
Cyclophosphamide
4
AP 1903 reagent
4
romiplostim
3
peginesatide
3
luspatercept
3
hetrombopag
3
hematide
3
Vancomycin
3
ON 01910
3
Enoxaparin
3
Azacitidine
3
ACE-011
3
venetoclax
2
telapristone acetate
2
roxadustat
2
iron isomaltoside 1000
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
ferric carboxymaltose
×
Classical hematology
×
Clear all
NCT01100879
2022-05-09
AOC-MM
Vifor Pharma
Phase 4
Terminated
3 enrolled
NCT01101399
2013-12-18
FID-CHEMO
Vifor Pharma
Phase 3
Completed
19 enrolled